



- (51) **International Patent Classification:**
A61K 31/559 (2006.01) *A61P 27/02* (2006.01)
- (21) **International Application Number:**
PCT/US2011/048048
- (22) **International Filing Date:**
17 August 2011 (17.08.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/374,439 17 August 2010 (17.08.2010) US
- (71) **Applicant** (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (for US only): **JIANG, Guang-Liang** [CN/US]; 36 Trailing Ivy, Irvine, California 92620 (US). **IM, Wha Bin** [US/US]; 70 Palatine, Apt. 305, Irvine, California 92612 (US). **WHEELER, Larry A.** [US/US]; 18 Valley View, Irvine, California 92612 (US). **WHITCUP, Scott M.** [US/US]; 27591 Lost Trail Drive, Laguna Hills, California 92653 (US).
- (74) **Agents:** **FORRESTAL, Kevin** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** EP2 OR EP4 AGONISTS FOR TREATING CORNEAL HAZE



(57) **Abstract:** Disclosed herein are compositions and methods for treating corneal haze. Compositions and methods of use comprise therapeutically effective amounts of compounds that agonize the EP2 and/or EP4 receptor. Administration of the disclosed compounds can prevent and treat corneal haze development.

